Index RUT P/E - EPS (ttm) -0.10 Insider Own 7.23% Shs Outstand 165.53M Perf Week -2.71%
Market Cap 1.13B Forward P/E 37.52 EPS next Y 0.18 Insider Trans -2.74% Shs Float 153.93M Perf Month -10.03%
Enterprise Value 1.30B PEG - EPS next Q 0.02 Inst Own 58.60% Short Float 11.04% Perf Quarter -10.14%
Income -15.64M P/S 4.25 EPS this Y 94.03% Inst Trans 2.97% Short Ratio 8.44 Perf Half Y -6.58%
Sales 266.14M P/B - EPS next Y 923.19% ROA -4.52% Short Interest 17.00M Perf YTD -13.12%
Book/sh -0.01 P/C 12.35 EPS next 5Y - ROE - 52W High 10.08 -32.34% Perf Year 89.44%
Cash/sh 0.55 P/FCF 113.50 EPS past 3/5Y 37.81% 40.01% ROIC -6.24% 52W Low 3.51 94.30% Perf 3Y 477.97%
Dividend Est. - EV/EBITDA 57.85 Sales past 3/5Y 59.99% 136.89% Gross Margin 80.48% Volatility 4.24% 4.13% Perf 5Y -0.29%
Dividend TTM - EV/Sales 4.88 EPS Y/Y TTM 76.50% Oper. Margin 3.68% ATR (14) 0.32 Perf 10Y -
Dividend Ex-Date - Quick Ratio 1.35 Sales Y/Y TTM 42.05% Profit Margin -5.88% RSI (14) 39.33 Recom 1.43
Dividend Gr. 3/5Y - - Current Ratio 1.93 EPS Q/Q 103.31% SMA20 -5.98% Beta 0.65 Target Price 11.14
Payout - Debt/Eq - Sales Q/Q 37.06% SMA50 -5.94% Rel Volume 0.45 Prev Close 6.91
Employees 394 LT Debt/Eq - Earnings Mar 02 BMO SMA200 1.31% Avg Volume 2.01M Price 6.82
IPO Jun 21, 2018 Option/Short Yes / Yes EPS/Sales Surpr. -100.00% -0.17% Trades
Volume 908,175 Change -1.30%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-09-25 Initiated Barclays
Overweight
$9
Aug-12-25 Resumed H.C. Wainwright
Buy
$10
Nov-11-24 Downgrade Piper Sandler
Overweight → Neutral
$3
Mar-28-24 Initiated Oppenheimer
Outperform
$5
Aug-28-23 Initiated Craig Hallum
Buy
$4.50
Oct-21-22 Initiated Jefferies
Buy
$4
Apr-28-22 Initiated Craig Hallum
Buy
$6.50
Nov-17-21 Initiated SVB Leerink
Outperform
$6
Oct-29-21 Initiated H.C. Wainwright
Buy
$4
Apr-07-21 Resumed RBC Capital Mkts
Outperform
$11
Feb-18-20 Initiated Piper Sandler
Overweight
$12
Jul-16-18 Initiated RBC Capital Mkts
Outperform
$24
Jul-16-18 Initiated Leerink Partners
Outperform
$24
Jul-16-18 Initiated Jefferies
Buy
$23
Show Previous Ratings
Jan-08-26 07:00AM
Jan-02-26 04:15PM
Dec-31-25 07:09PM
Dec-18-25 01:13PM
Dec-01-25 07:00AM
09:30AM
Loading…
Nov-06-25 09:30AM
08:30AM
07:00AM
Oct-30-25 06:45PM
Oct-23-25 07:30AM
Oct-20-25 12:00PM
09:15AM
Oct-16-25 09:06AM
Oct-13-25 07:58AM
Oct-03-25 04:15PM
12:00PM
Loading…
12:00PM
09:15AM
Sep-09-25 12:00PM
Aug-29-25 05:09AM
Aug-25-25 07:00AM
Aug-12-25 12:00PM
09:15AM
Aug-07-25 10:30AM
(Associated Press Finance) +20.22%
09:30AM
08:35AM
07:32AM
(Associated Press Finance)
07:00AM
Jul-31-25 07:30AM
Jul-03-25 08:19AM
Jun-03-25 07:30AM
07:30AM
Loading…
May-20-25 07:30AM
May-12-25 03:54PM
May-09-25 03:21AM
May-08-25 08:20AM
07:17AM
(Associated Press Finance)
07:00AM
May-07-25 12:08PM
11:51AM
May-05-25 05:30PM
May-01-25 07:00AM
Apr-22-25 06:46PM
Apr-17-25 07:00AM
Mar-28-25 08:00AM
Mar-27-25 10:18AM
Mar-20-25 10:13AM
Mar-19-25 04:49PM
Mar-17-25 08:00AM
Mar-07-25 02:08AM
Mar-06-25 09:30AM
08:15AM
07:22AM
(Associated Press Finance)
07:00AM
Feb-27-25 07:00AM
Feb-26-25 10:00AM
Feb-24-25 08:00AM
Feb-05-25 08:00AM
Jan-21-25 09:00AM
Jan-11-25 07:27AM
Jan-10-25 07:00AM
Jan-06-25 04:15PM
Nov-26-24 07:00AM
Nov-09-24 02:06AM
Nov-08-24 09:30AM
08:10AM
07:10AM
(Associated Press Finance)
07:00AM
Oct-31-24 08:00AM
Oct-04-24 04:05PM
Aug-22-24 07:00AM
Aug-08-24 08:25AM
07:30AM
(Associated Press Finance)
07:00AM
Aug-01-24 10:01AM
Jul-25-24 07:00AM
Jul-24-24 09:55AM
Jul-08-24 07:00AM
Jul-03-24 01:05PM
Jun-03-24 07:00AM
May-30-24 07:30AM
07:00AM
May-10-24 03:21PM
12:36PM
12:27AM
(Thomson Reuters StreetEvents)
May-09-24 11:55AM
08:10AM
07:11AM
(Associated Press Finance)
07:00AM
May-06-24 07:42AM
07:00AM
May-02-24 07:00AM
Apr-03-24 04:05PM
Apr-02-24 07:00AM
Mar-07-24 01:47PM
11:56AM
Mar-06-24 11:16PM
(Thomson Reuters StreetEvents) -19.48%
12:52PM
08:15AM
07:17AM
(Associated Press Finance)
07:02AM
07:00AM
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hecht Beth See Remarks Feb 02 '26 Sale 7.45 16,667 124,147 1,243,174 Feb 02 06:11 PM McCulloch Kevin See Remarks Jan 08 '26 Sale 8.00 15,000 120,000 1,685,426 Jan 09 05:34 PM KEVIN MCCULLOCH Officer Jan 08 '26 Proposed Sale 7.21 60,000 432,600 Jan 08 04:22 PM Shannon John Patrick Jr See Remarks Jan 05 '26 Option Exercise 1.63 92,301 149,998 2,797,647 Jan 06 06:14 PM Shannon John Patrick Jr See Remarks Jan 05 '26 Sale 7.08 24,907 176,257 2,705,346 Jan 06 06:14 PM Hecht Beth See Remarks Jan 02 '26 Sale 7.43 16,667 123,776 1,308,103 Jan 05 06:01 PM JOHN H JOHNSON Director Dec 19 '25 Proposed Sale 7.22 135,402 977,034 Dec 19 06:15 PM JOHNSON JOHN Director Dec 19 '25 Sale 7.22 135,400 977,019 698,083 Dec 19 05:17 PM BORMANN-KENNEDY BARBARA-JEAN A Director Dec 12 '25 Sale 7.09 15,000 106,414 142,500 Dec 15 05:24 PM BARBARA-JEAN A BORMANN-KENNEDY Director Dec 12 '25 Proposed Sale 7.01 15,000 105,150 Dec 12 04:20 PM Hecht Beth See Remarks Dec 01 '25 Sale 7.01 16,667 116,781 1,320,176 Dec 02 05:14 PM Shannon John Patrick Jr See Remarks Nov 14 '25 Option Exercise 1.55 87,100 135,005 2,730,253 Nov 17 05:58 PM Shannon John Patrick Jr See Remarks Nov 13 '25 Option Exercise 1.55 8,970 13,904 2,666,395 Nov 17 05:58 PM Shannon John Patrick Jr See Remarks Nov 13 '25 Sale 7.46 23,242 173,402 2,643,153 Nov 17 05:58 PM Hecht Beth See Remarks Nov 11 '25 Sale 7.40 16,667 123,296 1,336,843 Nov 13 06:59 PM JOHN SHANNON Director Nov 13 '25 Proposed Sale 7.59 48,149 365,451 Nov 13 04:25 PM BETH HECHT Officer Nov 11 '25 Proposed Sale 7.72 66,668 514,677 Nov 12 07:02 AM PERSKY MARLA Director Sep 11 '25 Sale 7.72 15,500 119,610 142,000 Sep 12 05:09 PM MARLA PERSKY Director Sep 11 '25 Proposed Sale 7.81 15,500 121,055 Sep 11 04:24 PM SHERMAN JEFFREY W Director Aug 28 '25 Option Exercise 6.66 47,040 313,286 261,420 Aug 29 05:21 PM SHERMAN JEFFREY W Director Aug 28 '25 Sale 7.92 42,232 334,515 219,188 Aug 29 05:21 PM JEFFREY SHERMAN Director Aug 28 '25 Proposed Sale 7.92 42,232 334,511 Aug 28 04:09 PM JOHNSON JOHN Director Aug 13 '25 Sale 7.32 107,500 786,459 833,483 Aug 15 04:57 PM HALKUFF DAWN Director Aug 12 '25 Sale 7.28 42,500 309,226 115,000 Aug 13 04:47 PM JOHN H JOHNSON Director Aug 13 '25 Proposed Sale 7.32 107,500 786,452 Aug 13 04:08 PM DAWN HALKUFF Director Aug 12 '25 Proposed Sale 7.28 42,500 309,226 Aug 12 04:23 PM McCulloch Kevin See Remarks Jun 13 '25 Buy 4.38 25,000 109,475 1,708,585 Jun 16 04:26 PM Fairley Ricki Louise Director May 09 '25 Proposed Sale 4.90 56,667 277,668 May 09 05:28 PM Hecht Beth See Remarks Mar 20 '25 Sale 5.43 40,000 217,244 1,353,510 Mar 21 05:31 PM Hecht Beth Officer Mar 20 '25 Proposed Sale 5.14 40,000 205,600 Mar 20 05:26 PM
